TG Therapeutics (TGTX) Stock Overview
A commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
TGTX Community Fair Values
Create NarrativeSee what 107 others think this stock is worth. Follow their fair value or set your own to get alerts.
TG Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$35.12 |
| 52 Week High | US$46.48 |
| 52 Week Low | US$22.61 |
| Beta | 1.97 |
| 1 Month Change | 8.50% |
| 3 Month Change | -6.60% |
| 1 Year Change | 44.82% |
| 3 Year Change | 552.79% |
| 5 Year Change | 34.25% |
| Change since IPO | 2,990.86% |
Recent News & Updates
Recent updates
What TG Therapeutics, Inc.'s (NASDAQ:TGTX) 26% Share Price Gain Is Not Telling You
Sep 30
Revenues Not Telling The Story For TG Therapeutics, Inc. (NASDAQ:TGTX)
Jul 29TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-Cel
Jun 25TG Therapeutics' (NASDAQ:TGTX) Weak Earnings May Only Reveal A Part Of The Whole Picture
May 16Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Apr 09TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials
Mar 14Risks To Shareholder Returns Are Elevated At These Prices For TG Therapeutics, Inc. (NASDAQ:TGTX)
Mar 02TG Therapeutics (NASDAQ:TGTX) Has Debt But No Earnings; Should You Worry?
Jan 07Optimistic Investors Push TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Up 27% But Growth Is Lacking
Nov 07TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates
Nov 05
BRIUMVI's Breakthrough In MS Market Promises Robust Revenue Surge And Expanding Therapeutic Horizons
Strong sales of BRIUMVI and strategic expansions such as innovative versions aim to secure market dominance in treating relapsing multiple sclerosis.TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback
Aug 07Hold TG Therapeutics For Intriguing Outcomes
Jun 12TG Therapeutics: Less Room For Doubt About Briumvi
May 03TG Therapeutics: Briumvi Growth Story Appears Intact
Mar 01TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
Jan 10Shareholder Returns
| TGTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.9% | 3.5% | 1.2% |
| 1Y | 44.8% | 3.1% | 16.3% |
Return vs Industry: TGTX exceeded the US Biotechs industry which returned 3.1% over the past year.
Return vs Market: TGTX exceeded the US Market which returned 16.3% over the past year.
Price Volatility
| TGTX volatility | |
|---|---|
| TGTX Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: TGTX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: TGTX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 370 | Mike Weiss | www.tgtherapeutics.com |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody.
TG Therapeutics, Inc. Fundamentals Summary
| TGTX fundamental statistics | |
|---|---|
| Market cap | US$5.12b |
| Earnings (TTM) | US$60.46m |
| Revenue (TTM) | US$454.07m |
Is TGTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TGTX income statement (TTM) | |
|---|---|
| Revenue | US$454.07m |
| Cost of Revenue | US$59.22m |
| Gross Profit | US$394.85m |
| Other Expenses | US$334.39m |
| Earnings | US$60.46m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.41 |
| Gross Margin | 86.96% |
| Net Profit Margin | 13.31% |
| Debt/Equity Ratio | 88.9% |
How did TGTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/21 16:22 |
| End of Day Share Price | 2025/10/20 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TG Therapeutics, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Madhu Kumar | B. Riley Securities, Inc. |